Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.
Daniel Carrizosa, MD, MS
Advertisement
Articles by Daniel Carrizosa, MD, MS
Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
2
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
3
Dr Hurvitz on Updated PFS Data From the SERENA-6 Trial in Breast Cancer
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5